Cargando…

Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung

BACKGROUND: The overall prognosis of non-small cell lung cancer (NSCLC) is poor, and currently only patients with localized disease are potentially curable. Therefore, preferably non-invasively determined biomarkers that detect NSCLC patients at early stages of the disease are of high clinical relev...

Descripción completa

Detalles Bibliográficos
Autores principales: Djureinovic, Dijana, Pontén, Victor, Landelius, Per, Al Sayegh, Sahar, Kappert, Kai, Kamali-Moghaddam, Masood, Micke, Patrick, Ståhle, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664554/
https://www.ncbi.nlm.nih.gov/pubmed/31357969
http://dx.doi.org/10.1186/s12885-019-5943-3
_version_ 1783439908504862720
author Djureinovic, Dijana
Pontén, Victor
Landelius, Per
Al Sayegh, Sahar
Kappert, Kai
Kamali-Moghaddam, Masood
Micke, Patrick
Ståhle, Elisabeth
author_facet Djureinovic, Dijana
Pontén, Victor
Landelius, Per
Al Sayegh, Sahar
Kappert, Kai
Kamali-Moghaddam, Masood
Micke, Patrick
Ståhle, Elisabeth
author_sort Djureinovic, Dijana
collection PubMed
description BACKGROUND: The overall prognosis of non-small cell lung cancer (NSCLC) is poor, and currently only patients with localized disease are potentially curable. Therefore, preferably non-invasively determined biomarkers that detect NSCLC patients at early stages of the disease are of high clinical relevance. The aim of this study was to identify and validate novel protein markers in plasma using the highly sensitive DNA-assisted multiplex proximity extension assay (PEA) to discriminate NSCLC from other lung diseases. METHODS: Plasma samples were collected from a total of 343 patients who underwent surgical resection for different lung diseases, including 144 patients with lung adenocarcinoma (LAC), 68 patients with non-malignant lung disease, 83 patients with lung metastasis of colorectal cancers and 48 patients with typical carcinoid. One microliter of plasma was analyzed using PEA, allowing detection and quantification of 92 established cancer related proteins. The concentrations of the plasma proteins were compared between disease groups. RESULTS: The comparison between LAC and benign samples revealed significantly different plasma levels for four proteins; CXCL17, CEACAM5, VEGFR2 and ERBB3 (adjusted p-value < 0.05). A multi-parameter classifier was developed to discriminate between samples from LAC patients and from patients with non-malignant lung conditions. With a bootstrap aggregated decision tree algorithm (TreeBagger), a sensitivity of 93% and specificity of 64% was achieved to detect LAC in this risk population. CONCLUSIONS: By applying the highly sensitive PEA, reliable protein profiles could be determined in microliter amounts of plasma. We further identified proteins that demonstrated different plasma concentration in defined disease groups and developed a signature that holds potential to be included in a screening assay for early lung cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5943-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6664554
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66645542019-08-05 Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung Djureinovic, Dijana Pontén, Victor Landelius, Per Al Sayegh, Sahar Kappert, Kai Kamali-Moghaddam, Masood Micke, Patrick Ståhle, Elisabeth BMC Cancer Research Article BACKGROUND: The overall prognosis of non-small cell lung cancer (NSCLC) is poor, and currently only patients with localized disease are potentially curable. Therefore, preferably non-invasively determined biomarkers that detect NSCLC patients at early stages of the disease are of high clinical relevance. The aim of this study was to identify and validate novel protein markers in plasma using the highly sensitive DNA-assisted multiplex proximity extension assay (PEA) to discriminate NSCLC from other lung diseases. METHODS: Plasma samples were collected from a total of 343 patients who underwent surgical resection for different lung diseases, including 144 patients with lung adenocarcinoma (LAC), 68 patients with non-malignant lung disease, 83 patients with lung metastasis of colorectal cancers and 48 patients with typical carcinoid. One microliter of plasma was analyzed using PEA, allowing detection and quantification of 92 established cancer related proteins. The concentrations of the plasma proteins were compared between disease groups. RESULTS: The comparison between LAC and benign samples revealed significantly different plasma levels for four proteins; CXCL17, CEACAM5, VEGFR2 and ERBB3 (adjusted p-value < 0.05). A multi-parameter classifier was developed to discriminate between samples from LAC patients and from patients with non-malignant lung conditions. With a bootstrap aggregated decision tree algorithm (TreeBagger), a sensitivity of 93% and specificity of 64% was achieved to detect LAC in this risk population. CONCLUSIONS: By applying the highly sensitive PEA, reliable protein profiles could be determined in microliter amounts of plasma. We further identified proteins that demonstrated different plasma concentration in defined disease groups and developed a signature that holds potential to be included in a screening assay for early lung cancer detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5943-3) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-29 /pmc/articles/PMC6664554/ /pubmed/31357969 http://dx.doi.org/10.1186/s12885-019-5943-3 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Djureinovic, Dijana
Pontén, Victor
Landelius, Per
Al Sayegh, Sahar
Kappert, Kai
Kamali-Moghaddam, Masood
Micke, Patrick
Ståhle, Elisabeth
Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title_full Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title_fullStr Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title_full_unstemmed Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title_short Multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
title_sort multiplex plasma protein profiling identifies novel markers to discriminate patients with adenocarcinoma of the lung
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664554/
https://www.ncbi.nlm.nih.gov/pubmed/31357969
http://dx.doi.org/10.1186/s12885-019-5943-3
work_keys_str_mv AT djureinovicdijana multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT pontenvictor multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT landeliusper multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT alsayeghsahar multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT kappertkai multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT kamalimoghaddammasood multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT mickepatrick multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung
AT stahleelisabeth multiplexplasmaproteinprofilingidentifiesnovelmarkerstodiscriminatepatientswithadenocarcinomaofthelung